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Abstract 
Background: Flavonoids are bio-active specialized plant metabolites which mainly occur as different glycosides. Due 
to the increasing market demand, various biotechnological approaches have been developed which use Escherichia 
coli as a microbial catalyst for the stereospecific glycosylation of flavonoids. Despite these efforts, most processes still 
display low production rates and titers, which render them unsuitable for large-scale applications.
Results: In this contribution, we expanded a previously developed in vivo glucosylation platform in E. coli W, into an 
efficient system for selective galactosylation and rhamnosylation. The rational of the novel metabolic engineering 
strategy constitutes of the introduction of an alternative sucrose metabolism in the form of a sucrose phosphorylase, 
which cleaves sucrose into fructose and glucose 1-phosphate as precursor for UDP-glucose. To preserve these inter-
mediates for glycosylation purposes, metabolization reactions were knocked-out. Due to the pivotal role of UDP-glu-
cose, overexpression of the interconverting enzymes galE and MUM4 ensured the formation of both UDP-galactose 
and UDP-rhamnose, respectively. By additionally supplying exogenously fed quercetin and overexpressing a flavonol 
galactosyltransferase (F3GT) or a rhamnosyltransferase (RhaGT), 0.94 g/L hyperoside (quercetin 3-O-galactoside) and 
1.12 g/L quercitrin (quercetin 3-O-rhamnoside) could be produced, respectively. In addition, both strains showed 
activity towards other promising dietary flavonols like kaempferol, fisetin, morin and myricetin.
Conclusions: Two E. coli W mutants were engineered that could effectively produce the bio-active flavonol glyco-
sides hyperoside and quercitrin starting from the cheap substrates sucrose and quercetin. This novel fermentation-
based glycosylation strategy will allow the economically viable production of various glycosides.
Keywords: Galactosylation, Rhamnosylation, Glycosylation, Hyperoside, Quercitrin, Escherichia coli W, Metabolic 
engineering, Flavonoids
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Background
Flavonoids are a class of plant secondary metabolites, 
which are chemically characterized by a 15-carbon back-
bone that consists of two phenyl rings and a heterocyclic 
ring. To date, over 10,000 flavonoids have been charac-
terized from various plants, which are classified accord-
ing to their chemical structure, i.e., the number and 
presence of hydroxyl groups and further functional group 
modifications into various subgroups, such as anthoxan-
thins, flavanones, and flavanonols [1, 2].
In recent years flavonoids have garnered much atten-
tion from various application domains because of the 
various beneficial effects on human health that have been 
attributed to them, such as anticancer [3] and antioxi-
dant [4] to anti-inflammatory [5], antimicrobial [6] and 
antiviral [6, 7] effects. As final step in their biosynthesis, 
flavonoids are often glycosylated which has a profound 
effect on their solubility, stability and bio-activity [8, 9]. 
For example, the best studied flavonol quercetin, which 
makes up to 75 % of our daily flavonoid intake, predomi-
nantly occurs as different glycosides. Over 350 different 
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quercetin glycoforms have been reported to date with 
varying pharmacological properties [10, 11]. In this con-
text, hyperoside (quercetin 3-O-galactoside) and querci-
trin (quercetin 3-O-rhamnoside) (Fig. 1) have gained a lot 
of attention as valuable products for the pharmaceutical 
industry e.g., as powerful antioxidants with cytoprotec-
tive effects [12–15] and as promising antiviral agents that 
block replication of the influenza virus [16] or inhibit the 
viruses hepatitis B [17] and SARS [18]. Furthermore, they 
have been attributed with anti-inflammatory [19, 20], 
antidepressant [21, 22], apoptotic [23] and antifungal [24] 
activities, rendering them interesting therapeutics result-
ing in a steadily increasing market demand.
To date, the majority of quercetin and its glycosides are 
extracted from plant material, which is generally a labori-
ous and low-yielding process requiring many purification 
steps [25]. In vitro plant cell cultures or engineered plants 
can be used to overcome the low yields and improve pro-
duction [26–28], however since metabolic engineering 
of plants is both very controversial and still in its infancy 
[29], this approach is often restricted to small-scale 
production. Although chemical synthesis of quercetin 
(glycosides) has proven to be feasible [30–32], stereose-
lective formation of glycosidic linkages is often hampered 
by the presence of various reactive groups [33], which 
requires many protecting and deprotecting steps [34]. In 
addition, the generation of toxic waste and a low atom-
efficiency [35] render these production processes neither 
sustainable nor economically viable.
As a result, in the last two decades enormous efforts 
have been invested in the development of alternative pro-
duction methods for these specialized (secondary) plant 
metabolites [36]. Advances in the fields of protein engi-
neering, systems and synthetic biology have accelerated 
these efforts to transform model organisms like Escheri-
chia coli and Saccharomyces cerevisiae in real microbial 
cell factories for the sustainable production of flavonoids 
[37–39]. Subsequently, strategies for the in  vivo glyco-
sylation of flavonoids have also been developed. These 
are typically based on both the overexpression of specific 
glycosyltransferases, which transfer a sugar residue from 
an activated nucleotide sugar to an aglycon in a stereo- 
and regioselective way, and the engineering or introduc-
tion of the targeted nucleotide sugar pathway. In this way, 
Fig. 1 Transformation of E. coli W into a sucrose-based galactosylation and rhamnosylation platform. The metabolic engineering strategy applied 
makes use of several gene deletions (indicated in red) and overexpressions of genes (indicated in green). The rational of a split metabolism is 
applied, whereby sucrose is divided by sucrose phosphorylase (BaSP) in fructose to be used for growth and a glucose 1-phosphate as activated pre-
cursor for UDP-glucose. The latter is a universal pivot molecule for the formation of UDP-galactose and UDP-rhamnose, interconversions catalyzed 
by the enzymes GalE and MUM4, respectively. To ensure growth-coupled production, various genes, involved in the metabolization of these UDP-
sugars and their precursors, were knocked out (shown in red). The production of the bioactive quercetin glycosides hyperoside and quercitrin was 
chosen to evaluate the versatility of the engineered production platform. Finally, the introduction of either the glycosyltransferase F3GT or RhaGT 
ensures efficient galactosylation or rhamnosylation, respectively
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various quercetin glycosides have already been produced 
in E. coli such as the naturally occurring 3-O-glucoside 
[40], 3-O-xyloside [41] and 3,7-O-bisrhamnoside [42], or 
the new-to-nature quercetin 3-O-(6-deoxytalose) [43]. 
However, despite these engineering efforts, the reported 
product rates and titers are still in the milligram range, 
rendering these microbial production hosts unsuitable 
for industrial applications. The developed production 
processes are typically biphasic bioconversion processes 
using resting cells, which makes it difficult to improve 
production rates [44]. Furthermore, such systems often 
entail expensive growth media or the addition of enzyme 
inducers, making the overall process very costly.
To tackle these problems, we previously developed 
an efficient platform for the glucosylation of small mol-
ecules in E. coli W [45]. Through metabolic engineer-
ing, a mutant was created which couples the production 
of glucosides to growth, using sucrose as a cheap and 
sustainable carbon source. By introducing the sucrose 
phosphorylase from Bifidobacterium adolescentis (BaSP) 
sucrose can be split into fructose to be used for growth 
purposes and glucose 1-phosphate (glc1P) to be used 
as precursor for UDP-glucose (UDP-glc) formation 
(Fig. 1). To impede the conversion of glc1P into biomass 
precursors, several endogenous genes involved in its 
metabolization such as phosphoglucomutase (pgm) and 
glucose-1-phosphatase (agp) were knocked out. Sub-
sequently, glc1P can efficiently be channeled towards 
UDP-glc by overexpressing the uridylyltransferase from 
Bifidobacterium bifidum (ugpA). Metabolization of 
UDP-glc is prevented by knocking out the UDP-sugar 
hydrolase (ushA) and the galactose operon (galETKM). 
However, in view of the pivotal role of UDP-glc in the 
production of a large variety of UDP-sugars, this glu-
cosylation system can easily be extended towards other 
UDP-sugars, such as UDP-galactose (UDP-gal), UDP-
rhamnose (UDP-rha) and UDP-glucuronate.
In the present contribution, this previously developed 
E. coli W-based glucosylation platform is transformed 
into a platform for galactosylation and rhamnosyla-
tion (Fig.  1), whose potential is demonstrated using the 
galactosylation and rhamnosylation of exogenously fed 
quercetin yielding hyperoside and quercitrin, respec-
tively, as case study.
Results and discussion
Using E. coli W as a host for in vivo glycosylation
Escherichia coli W is a fast-growing non-pathogenic 
strain which tolerates osmotic stress, acidic condi-
tions, and can be cultured to high cell densities, making 
it an attractive host for industrial fermentations [46]. 
Moreover, E. coli W is able to grow on sucrose as sole 
carbon source [46], which is an emerging feedstock for 
the production of bio-products. Hence, E. coli W was 
selected as host for sucrose-based in  vivo glycosylation. 
Prior to the production of the glycosides hyperoside 
and quercitrin in E. coli W, the toxicity of their aglycon 
quercetin was investigated. To this end, the wild type 
(WT) strain was grown on minimal sucrose medium 
containing different concentrations of quercetin (0, 0.15 
and 1.5 g/L). The specific growth rates (h−1) (0.96 ± 0.06, 
0.92 ± 0.05 and 0.87 ± 0.06, respectively) were not sig-
nificantly different (pANOVA = 0.12) nor from the one pre-
viously determined for the WT [45] (p = 0.69, p = 0.98 
and p = 0.68, respectively). On the other hand, the opti-
cal density at 600 nm after 24 h incubation (6.36 ± 0.12, 
5.18  ±  0.16 and 4.77  ±  0.20, respectively) was lower 
(about 20 %) when quercetin was added (p = 0.0002 and 
p =  0.0001). No significant difference in optical density 
could be observed between 0.15 and 1.5  g/L querce-
tin (p = 0.14). In view of the above, it was opted to add 
1.5  g/L quercetin to evaluate the potential of the devel-
oped glycosylation platform.
To evaluate the in  vivo glycosylation potential, strains 
sGAL1 and sRHA1, which constitutively express the fla-
vonol 3-O-galactosyltransferase from Petunia hybrida 
and the flavonol 3-O-rhamnosyltransferase from A. thali-
ana, respectively, were cultured in minimal medium with 
1.5 g/L of quercetin for 16 h. TLC analysis of the super-
natants of both cultures yielded two new yellow product 
spots. The TLC spot obtained from the sGAL1 culture, 
which had the same retention time as the hyperoside 
standard (Rf =  0.5), was subsequently purified and ana-
lyzed. Both NMR and MS analysis confirmed the produc-
tion of quercetin 3-O-galactoside. However, the product 
spot obtained from the sRHA1 culture had a different 
retention factor (Rf = 0.55) than the quercitrin standard 
(Rf = 0.74), and was identified as isoquercitrin (quercetin 
3-O-glucoside). As opposed to other reports on wild type 
E. coli strains expressing RhaGT, which simultaneously 
produced quercitrin (quercetin 3-O-rhamnoside) and 
isoquercitrin [47, 48], no rhamnoside could be detected. 
Examination of the E. coli W genome revealed that the 
gene cluster responsible for the endogenous production 
of dTDP-rhamnose, which functions as an alternative 
rhamnosyldonor for RhaGT in E. coli B and K12 deriva-
tives [47], was not present [46, 49].
In a follow-up experiment, sGAL1 and sRHA1 were 
grown on minimal medium with two different concen-
trations (0.15 and 1.5 g/L) of quercetin. Growth and gly-
coside formation were monitored during 30 h. The final 
titers (Cp) and specific productivities (qp) are shown in 
Fig.  2. Remarkably, an increase in quercetin concentra-
tion resulted in a two to threefold increase in productivity 
and titer, indicating that quercetin supply is rate-limiting 
and crucial for efficient in  vivo glycosylation. However, 
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while sGAL1 continuously produced hyperoside dur-
ing the exponential phase, which is also reflected in the 
relatively high specific productivity, sRHA1 only started 
to accumulate significant amounts of isoquercitrin at 
the end of the exponential phase. This production start 
coincides with a reduction in specific growth rate, which 
dropped from 0.35 ± 0.04 to 0.06 ± 0.01 h−1.
Construction of an advanced sucrose‑based glycosylation 
strain
As described in detail in the Background section, we pre-
viously metabolically engineered E. coli  W to create a 
platform for in vivo glucosylation of small molecules [45]. 
In the original base glucosylation strain, sucrose phos-
phorylase encoded by BaSP was located on a medium-
copy plasmid and transcribed from a medium-strong 
constitutive promoter (P22) [50]. For reasons of com-
parison and flexibility, it was opted to integrate BaSP in 
the genome of E. coli W. In addition, chromosomal inte-
gration is advantageous because of a significant increase 
in gene stability. Since the level of gene expression can 
considerably be impacted by the genome integration 
site [51] due to structural differences such as supercoil-
ing DNA regions, two different DNA sites were assessed 
for BaSP integration, i.e., melA and glgC, which encode 
an α-galactosidase and a glucose-1-phosphate ade-
nylyltransferase, respectively. To this end, an adapted 
knockin-knockout procedure for large DNA fragments 
was applied, which is schematically shown in Addi-
tional file 1: Figure S2. BaSP under control of promoter 
P22 was knocked in at the two different loci in E. coli W 
ΔcscAR, which resulted in the E. coli W strains ΔcscAR 
ΔmelA::L4-P22-BaSP-L5 and ΔcscAR ΔglgC::L4-P22-
BaSP-L5. Their maximal specific growth rate (µmax) 
on minimal sucrose medium, which is shown in Fig.  3, 
was compared to the original strain ΔcscAR  +  pBaSP. 
The influence of the knockin locus on the maximal spe-
cific growth rate is clear. Interestingly, integration at 
the melA locus resulted in a strain with a µmax which 
was not significantly different from the reference strain 
ΔcscAR  +  pBaSP. In view of the latter and consider-
ing the aimed growth-coupled production, it was opted 
to integrate BaSP at the melA locus leading to the final 
production base strain E. coli W ΔcscAR Δpgm Δagp 
ΔushA ΔlacZYA::P22-lacY ΔgalETKM ΔmelA::L4-P22-
BaSP-L5 (sGLYC) as shown in Table 1.
Enhanced production of bio‑active quercetin glycoforms
In nature, UDP-glc serves as a pivot molecule in the 
formation of a variety of UDP-sugars [44]. For exam-
ple, using the interconverting enzymes UDP-glucose 
4-epimerase (GalE) and UDP-rhamnose synthase 
(MUM4) UDP-glc can be converted to UDP-gal and 
UDP-rha, respectively. Though GalE is natively present in 
E. coli W an alternative homologous epimerase (GalE2) 
from B. bifidum was also selected and cloned due to the 
Fig. 2 Comparison of the specific glycoside productivities (qp) and glycoside titers (Cp) for strains sGAL1, which produces the 3-O-galactoside, and 
sRHA1, which produces the 3-O-glucoside, when grown for 30 h on minimal medium containing 0.15 or 1.5 g/L of quercetin. Error bars represent 
standard deviations
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tight and complex regulation of GalE expression in E. 
coli W. On the other hand, UDP-rhamnose synthesis is 
restricted to plants. Due to lack of the rfb cluster [46] E. 
coli W is even unable to form endogenous dTDP-rham-
nose as alternative rhamnosyl donor. Hence, the MUM4 
gene from A. thaliana was expressed from plasmid 
pMUM4 to achieve UDP-rhamnose formation in E. coli 
(Fig. 1).
The constructed galactosylation (sGAL) and rhamno-
sylation (sRHA) strains were grown on minimal medium 
with two levels (0.15 and 1.5  g/L) of quercetin. Growth 
and production were monitored to determine the spe-
cific productivities, as shown in Fig.  4. Again, higher 
extracellular quercetin concentrations resulted in a five-
fold increase in qp. However, no significant difference in 
productivity was observed between sGAL2 and sGAL3 
at 1.5  g/L quercetin, indicating that UDP-galactose for-
mation is as efficient with both GalE homologs and not 
likely the rate limiting step. With sGAL3, the highest 
hyperoside productivity (68.7  mg/g CDW/h) and titer 
(0.94 g/L) were obtained, the latter being 3.5-fold higher 
compared to sGAL1.
In contrast to sRHA1, TLC analysis of the superna-
tant of the cultures of sRHA2 and sRHA3 resulted in a 
product spot with a retention factor that corresponds to 
quercitrin, which was confirmed by MS analysis, thus 
showing in vivo activity of MUM4. A quercitrin titer of 
1.18 g/L and specific productivity of 47.8 mg/g CDW/h 
were obtained after 30  h incubation of sRHA3 when 
1.5 g/L quercetin was added to the medium, which corre-
sponded to a 53 % conversion. Also 51 mg/L of isoquer-
citrin was produced extracellularly which corresponds 
with a quercitrin:isoquercitrin production ratio of 24:1. 
This suggests the preference of RhaGT for UDP-rham-
nose when different UDP-sugar donors are present. 
Possible explanations for the significantly lower specific 
productivity (fivefold decrease) of sRHA2 as compared to 
sRHA3 are either a higher metabolic burden [52] caused 
by the two plasmid system or a too limited activity of the 
native GalU, which could be insufficient for adequate 
UDP-glc formation [45].
To demonstrate the scalability of the developed bio-
process, strain sGAL3 was cultured in a 1-L bioreactor, 
which also ensures a constant pH set at 6.80 and avoid 
oxygen limitation. A detailed overview of the consump-
tion of sucrose, growth and hyperoside production is 
given in Fig.  5. After a lag-phase, the strain displayed a 
growth rate of 0.32 ± 0.02 h−1 while simultaneously pro-
ducing hyperoside. The observed specific productivity 
(65.9  ±  2.6  mg/g CDW/h) was comparable to the one 
obtained on shake flask scale. When nearly all querce-
tin was converted, hyperoside formation slowed down, 
which can be explained either by the observed correla-
tion between quercetin concentration and qp, or by the 
reported reversibility of F3GT [53]. It is likely that further 
improvements in titer and productivity can be realized 
by optimizing the supply of quercetin using a fed-batch 
system.
To the best of our knowledge, the results obtained in 
this study with the engineered sGAL and sRHA strains 
for the production of hyperoside and quercitrin are the 
highest reported to date both in terms of titer and pro-
duction rate. The maximal production rate obtained in 
this contribution was 6 to 50-fold higher compared to the 
maximal production rates (rp,max) of processes reported 
in the literature [47, 54] as is illustrated in Fig. 6.
The increased performance, in terms of titer and pro-
ductivity, obtained with the developed platform can be 
attributed to the use of a split metabolism in combination 
with optimally rerouting the flux from glucose 1-phos-
phate towards UDP-galactose and UDP-rhamnose. The 
undesired conversion of the activated sugars into biomass 
Fig. 3 Effect of the chromosomal integration locus of the knockin of BaSP on the growth rate. Strains were grown in shake flasks and the resulting 
maximal growth rates (µmax) were compared with E. coli W ΔcscAR with plasmid-based BaSP expression (+pBaSP). Error bars represent standard 
deviations
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is impeded by gene deletions, which guarantees a high 
product yield. In addition, since biomass formation, 
which is fueled by the fructose moiety of sucrose, and 
glycoside synthesis go hand in hand and subsequently 
are performed at the same time at a high rate, a high pro-
ductivity is equally guaranteed (one-step fermentation 
process).
Beyond quercetin: in vivo glycosylation of other flavonols
Besides quercetin also other flavonols such as kaemp-
ferol, fisetin, morin and myricetin significantly contribute 
to our daily flavonoid intake, which also have extremely 
diverse beneficial effects [55, 56]. As the sugar moiety is a 
major determinant of the intestinal absorption of dietary 
flavonoids and their subsequent bioactivity [57, 58], the 
Table 1 Plasmids and strains used in this study
Strain or plasmid Description References
Plasmids
pBaSP pUC57 vector expressing BaSP from B. adolescentis under control 
of P22
De Bruyn et al. [45]
pGalE pUC57 vector expressing galE from E. coli under control of P22 This study
pGalE2 pUC57 vector expressing galE2 from B. bifidum under control of 
P22
This study
pMUM4 pUC57 vector expressing codon optimized MUM4 from A. thali-
ana under control of P22
GeneArt®
pF3GT pUC57-Kan vector expressing codon optimized f3gt from Petu-
nia hybrida under control of P22
GeneArt®
pRhaGT pUC57-Kan vector expressing codon optimized RhaGT from A. 
thaliana under control of P22
GeneArt®
pBaSP/VvGT2/UgpA pCX-Kan vector expressing BaSP, vvGT2 and ugpA under control 
of P22
De Bruyn et al. [45]
pGalE/F3GT/UgpA pCX-Kan vector expressing galE, f3gt and ugpA under control of 
P22
This study
pGalE2/F3GT/UgpA pCX-Kan vector expressing galE2, f3gt and ugpA under control 
of P22
This study
pMUM4/RhaGT/UgpA pCX-Kan vector expressing MUM4, RhaGT and ugpA under 
control of P22
This study
pKD46 λ Red recombinase expression, Ampr Datsenko and Wanner [62]
pCP20 FLP recombinase expression, Ampr, Cmr Datsenko and Wanner [62]
pKD3 Cm cassette template, Cmr, Ampr Datsenko and Wanner [62]
pKD4 Kan cassette template, Kanr, Ampr Datsenko and Wanner [62]
Strains
E. coli DH5α General cloning host Coli Genetic Stock Center
E. coli W Escherichia coli W ATCC 9637 BCCM/LMG
E. coli W ΔcscAR E. coli W with cscAR-deleted De Bruyn et al. [45]
E. coli W ΔcscAR ΔmelA::L4-P22-BaSP-L5 E. coli W with cscAR and melA deleted and L4-P22-BaSP-L5 inte-
grated in the genome
This study
E. coli W ΔcscAR ΔglgC::L4-P22-BaSP-L5 E. coli W with cscAR and glgC deleted and L4-P22-BaSP-L5 inte-
grated in the genome
This study
E. coli W ΔcscAR Δpgm Δagp ΔushA ΔlacZYA::P22-lacY 
ΔgalETKM
E. coli W with cscAR, pgm, agp, ushA, lacZYA, melA and galETKM 
deleted and P22-lacY integrated in the genome
De Bruyn et al. [45]
E. coli W ΔcscAR Δpgm Δagp ΔushA ΔlacZYA::P22-lacY 
ΔgalETKM ΔmelA::P22-BaSP (sGLYC)
E. coli W with cscAR, pgm, agp, ushA, lacZYA, melA and galETKM 
deleted and P22-lacY and L4-P22-BaSP-L5 integrated in the 
genome
This study
sGAL1 E. coli W + pF3GT This study
sGAL2 sGLYC + pGalE/F3GT/UgpA This study
sGAL3 sGLYC + pGalE2/F3GT/UgpA This study
sRHA1 E. coli W + pRhaGT This study
sRHA2 sGLYC + pMUM4 + pRhaGT This study
sRHA3 sGLYC + pMUM4/RhaGT/UgpA This study
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potential of the created E. coli W mutants towards both 
galactosylation and rhamnosylation of various flavonols 
was investigated.
To this end, strains sGAL3 and sRHA3 were grown 
in tubes with 5  mL minimal medium, each containing 
1.5  g/L of either kaempferol, myricetin, morin or fise-
tin. Growth and production were monitored over 48 h 
and various spots were observed on TLC with similar 
retention factors as hyperoside and quercitrin. Mass 
spectrometry was used to identify the compounds 
produced, which confirmed the in vivo galactosylation 
of myricetin, kaempferol, morin and fisetin (Table  2). 
All compounds occurred with an m/z of [M  +  114], 
due to complexation with trifluoroacetic acid from the 
mobile phase. The galactoside of morin was produced 
at a slow rate, which is in accordance to the very low 
in  vitro activity of F3GT towards this flavonol [53]. A 
possible explanation for this limited activity may be the 
presence of an unusual hydroxyl group at the 2′ posi-
tion, which may sterically hinder deprotonation and 
Fig. 4 Comparison of the specific productivity qp of the sGAL (a hyperoside formation) and sRHA (b quercitrin formation) strains. Strains were 
grown on minimal medium containing 0.15 g/L (gray bars) and 1.5 g/L (black bars) quercetin. Error bars represent standard deviations
Fig. 5 Production of hyperoside (open inverted triangle) in a 1-L bioreactor on minimal medium containing 0.76 g/L quercetin (filled inverted triangle) 
by strain sGAL3. Cell dry weight (filled circle) was measured together with extracellular sucrose (filled square)
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consequent galactosylation of morin at hydroxyl group 
3 [59].
Incubation of sRHA3 with the different flavonols 
investigated showed two distinct glycoside spots on 
TLC, which corresponded to the 3-O-rhamnoside and 
3-O-glucoside. Kaempferol proved to be the best sub-
strate for RhaGT and was predominantly rhamno-
sylated (8:1 ratio), with a titer exceeding 400  mg/L, 
which is twofold higher than previously reported [47]. 
Fisetin on the other hand was efficiently glucosylated, 
yet the formation of its rhamnoside was not as efficient, 
with a titer below 5 mg/L. A similar preference towards 
glucoside formation was also observed with myricetin 
and morin, which indicates that the positioning of the 
hydroxyl groups is the determining factor for glycosyla-
tion with RhaGT. The production of the desired rham-
nosides, galactosides or glucosides may be improved 
considerably by using UGTs that are more specific 
towards certain flavonols and UDP-sugars. Transfor-
mation of the corresponding UGTs in the developed 
in vivo glycosylation strains presents a promising alter-
native for the large-scale production of various flavonol 
glycoforms, which are to date mainly extracted from 
plant material.
On the other hand, due to the pivotal role of UDP-glc, 
various other UDP-sugars can be formed in  vivo (e.g. 
UDP-glucuronate, UDP-xylose, UDP-arabinose). In com-
bination with the modularity of the developed glycosyla-
tion platform, which permits rapid introduction of any 
UGT or UDP-sugar pathway, virtually any glycoside can 
be produced. Hence, this demonstrates that the proposed 
microbial platform is a robust, versatile and efficient 
microbial cell factory for the glycosylation (e.g. gluco-
sylation, rhamnosylation, galactosylation) of small mol-
ecules. Although obtained productivities are the highest 
reported today and compete with the current production 
processes, further improvement can be limited due to 
solubility issues of the aglycon or of the glycoside. To this 
end follow-up research can focus on further metabolic 
engineering (e.g. introduction of the aglycon pathway 
allowing in vivo gradually production of the aglycon) or 
on process optimization [e.g. 2-phase (bilayer) fermen-
tation which enables in  situ recovery] to improve these 
issues.
Fig. 6 Comparison of the production rates obtained using the developed galactosylation and rhamnosylation platform (asterisk) with those 
reported in the literature for quercetin 3-O-rhamnoside [47], quercetin 3-O-galactoside [54], quercetin 3-O-arabinoside [66], quercetin 3-O-xyloside 
[66], quercetin 3-O-N-acetylglucosamine [67] and quercetin 3-O-glucoside [40]
Table 2 Galactosylation and  rhamnosylation potential 
of strains sGAL3 and sRHA3 respectively towards other fla-
vonols
Specific productivity (qp) and titer (Cp) reached after 48 h of incubation are 
shown
ND not detected
a 3-O-glucoside was also detected at 52 ± 17 mg/L
b 3-O-glucoside was also detected at 21.7 ± 6.2 mg/L










Kaempferol 84 ± 14 3.46 ± 0.86 416 ± 37a 12.1 ± 1.4
Myricetin 52 ± 7.1 2.88 ± 0.22 72.3 ± 9.1 2.8 ± 0.5
Morin 34 ± 5.8 1.65 ± 0.15 116 ± 21b 2.5 ± 1.5
Fisetin 134 ± 22 9.32 ± 0.55 403 ± 31c 11.3 ± 0.9
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Conclusions
In this contribution, a biotechnological platform was 
developed for the galactosylation and rhamnosylation of 
small molecules, such as secondary metabolite natural 
products, starting from a previously created glucosyla-
tion host. To this end, the routes to convert UDP-glucose 
into UDP-galactose and UDP-rhamnose were introduced 
by expressing a UDP-glucose epimerase (galE) and a 
UDP-rhamnose synthase (MUM4), respectively. As a 
proof of concept, the bio-active flavonol quercetin was 
selected for galactosylation and rhamnosylation, yield-
ing hyperoside (quercetin 3-O-galactoside) and querci-
trin (quercetin 3-O-rhamnoside), respectively. Next, the 
flavonol 3-O-galactosyltransferase (F3GT) from Petunia 
hybrida and the flavonol 3-O-rhamnosyltransferase from 
Arabidopsis thaliana (RhaGT) were overexpressed in the 
metabolically engineered E. coli W mutants. The strains 
created were able to produce 940 mg/L of hyperoside and 
1176  mg/L of quercitrin at specific production rates of 
68.7 mg/g CDW/h and 47.8 mg/g CDW/h, respectively, 
which are the highest reported to date. Interestingly, 
both GTs showed in  vivo activity towards other dietary 
flavonols, whereby for example over 400 mg/L of kaemp-
ferol 3-O-rhamnoside could be formed extracellularly.
Methods
Materials and molecular agents
All plasmids used were constructed using Gibson assem-
bly [60] or CLIVA [61]. All PCR fragments were ampli-
fied using Q5 polymerase from New England Biolabs 
(Ipswich, Massachusetts). Oligonucleotides were pur-
chased from IDT (Leuven, Belgium). The plasmids and 
bacterial strains used in this study are listed in Table 1. A 
list of primers for the creation of gene knockouts/knock-
ins and for the cloning of the expression plasmids is given 
in Additional file 2: Table S1. E. coli DH5α was used for 
plasmid cloning and propagation, while E. coli W was 
used for expression of the production plasmids and the 
creation of gene knockouts and knockins. Hyperoside, 
quercitrin, isoquercitrin, kaempferol and myricetin were 
purchased from Carbosynth (Berkshire, UK). All other 
chemicals used were purchased from Sigma Aldrich 
(Germany) unless otherwise indicated.
Creation of the production plasmids
The expression plasmids for the prod uction of hypero-
side and quercitrin were constructed as depicted in Addi-
tional file  3: Figure S1A−C. Plasmids pF3GT, pRhaGT 
and pMUM4 were synthesized by GeneArt® (Life Tech-
nologies). The f3gt sequence [Genbank: AF165148] from 
Petunia hybrida, and MUM4 [Genbank: AT1G53500] 
and RhaGT [Genbank: AF360160] from A. thaliana were 
codon optimized for E. coli (gene sequences are given 
in Figure S1D). The galE [Genbank: JW0742] and galE2 
[Genbank: KJ543703] sequences were amplified from the 
genomic DNA of E. coli and Bifidobacterium bifidum, 
respectively. CLIVA assembly resulted in the intermedi-
ary plasmid pBaSP/F3GT/UgpA (Figure S1A), which was 
subsequently used for the amplification of the F3GT/
UgpA backbone. Gibson assembly of the GalE or GalE2 
inserts with this backbone resulted in the final galacto-
sylation plasmids pGalE/F3GT/UgpA and pGalE2/F3GT/
UgpA, respectively (Figure S1B). Similarly, MUM4 and 
RhaGT were introduced using a 3-pieces Gibson assem-
bly (Figure S1C), resulting in the final rhamnosylation 
plasmid pMUM4/RhaGT/UgpA.
Creation of the E. coli W production mutants
The overall E. coli W knockout mutants were cre-
ated using the one step deletion system of Datsenko 
and Wanner [62]. The strategy for chromosomal inte-
gration of BaSP under control of the constitutive pro-
moter P22 flanked by L4 and L5 at the melA and glgC 
loci is depicted and explained in Additional file  1: Fig-
ure S2. Transformants were plated on minimal sucrose 
medium agar plates and grown overnight for screen-
ing. The in-house strain E. coli W ΔcscAR Δpgm Δagp 
ΔushA ΔlacZYA::P22-lacY ΔgalETKM [45] was used for 
the chromosomal integration of L4-P22-BaSP-L5 at the 
melA site, yielding the base strain sGLYC (Table 1). This 
strain and the E. coli W wild type were transformed with 
the production plasmids described above, resulting in 
the galactosylation (sGAL) and rhamnosylation (sRHA) 
strains given in Table 1.
Media
Composition of LB and minimal sucrose medium was 
described previously [45]. Minimal medium agar plates 
with sucrose (50 g/L) had the same composition as mini-
mal sucrose medium, but contained additionally 15 g/L of 
agarose. The agarose and salts were autoclaved separately 
at 121 °C for 21 min. Sucrose was filter sterilized through 
a 0.22 µm corning filter (Fisher, Belgium) and heated for 
1 min in a microwave oven at 800 W prior to mixing it 
with the warm agarose and salt solutions. 1 mL/L of min-
eral solution [45] was sterilely added prior to pouring the 
plates.
Growth in shake flasks and sampling
Escherichia coli W mutant precultures were grown in 5 mL 
LB medium with the antibiotics (50 μg/mL kanamycin or 
carbenicillin) required for maintenance and selection of 
the plasmids. The cultures were grown for 16  h at 37  °C 
and 200 rpm and used for the 2 % inoculation of 100 mL 
minimal sucrose medium in 500 mL shake flasks. For the 
production of hyperoside and quercitrin, quercetin was 
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added to the minimal medium at a concentration of 0.15 
or 1.5 g/L. Growth conditions were the same as previously 
described [45]. Samples were taken at regular intervals 
from the broth and, after centrifugation, the supernatant 
was used for the analysis and quantification of sugars. 
For the analysis of quercetin and its glycosides, 200 µL of 
the culture was collected and extracted with 800 µL ethyl 
acetate. The organic layer was collected, evaporated in a 
SpeedVac™ vacuum concentrator (Thermo Fisher, USA) 
and dissolved in 200 µL of DMSO for HPLC quantification.
Growth in bioreactors
The bioreactor set-up and fermentation conditions 
used are the same as previously described [45]. Produc-
tion experiments were performed on minimal sucrose 
medium without MOPS buffer and with the addition of 
quercetin as acceptor.
Product analysis and quantification
Culture samples were primarily analyzed by TLC on Silica 
gel 60 F254 precoated plates (Merck, Germany). All plates 
were run in a closed TLC chamber and developed using 
standard visualization techniques and agents: UV fluo-
rescence (254 nm) or by staining with 10 % (v/v) H2SO4 
and subsequent charring. The mobile phase for detect-
ing the various flavonols and corresponding glycosides 
consisted of an ethyl acetate:acetic acid:formic acid:water 
(100:11:11:27 v/v) mixture [63]. Product spot intensities of 
other flavonol glycosides were processed and quantified 
using ImageJ [64]. HPLC quantification of sucrose, fruc-
tose and glucose was performed using an X-bridge Amide 
column (35  μm, Waters, USA) as described previously 
[45]. Quercetin, hyperoside, quercitrin and isoquercitrin 
were detected with the method described by Pandey et al. 
[41] using a Varian HPLC system (Agilent technologies, 
California). Mass spectrometry for determination of the 
various flavonol glycosides was performed with a Micro-
mass Quattro LC (McKinley Scientific, USA). Detection 
was performed in negative mode ESI-224 MS with a capil-
lary voltage of 2.53 kV, a cone voltage of 20 V, cone and 
desolvation gas flows of 93 and 420 L/h, and source and 
cone temperatures of 150 and 350 °C, respectively.
Purification and structural elucidation of compounds
Quercetin glycosides were extracted from the broth with 
an equal volume of ethyl acetate after which the organic 
layer was evaporated to dryness. The remaining prod-
uct was dissolved in the solvent system described above 
and run on a preparative TLC plate. The band containing 
hyperoside (Rf 0.53) or quercitrin (Rf 0.75) was scraped 
off, extracted with ethyl acetate and evaporated to yield a 
bright yellow powder. Products were confirmed by NMR. 
Spectra were reported elsewhere [47, 65].
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